High prevalence and clinical impact of dynapenia and sarcopenia in Japanese patients with type 1 and type 2 diabetes: Findings from the Impact of Diabetes Mellitus on Dynapenia study

Hiroyasu Mori1, Akio Kuroda1, Sumiko Yoshida2, Tetsuyuki Yasuda3, Yutaka Umayahara4, Sayoko Shimizu4, Kayoko Ryomoto5, Kazutomi Yoshiuchi6, Tsunehiko Yamamoto7, Takaaki Matsuoka8, Ichiro Shimomura8, Munehide Matsuhsisa1*

1Diabetes Therapeutics and Research Center, Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan, 2Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan, 3Department of Endocrinology and Metabolism, Osaka Police Hospital, Osaka, Japan, 4Osaka General Medical Center, Osaka, Japan, 5Osaka Rosai Hospital, Osaka, Japan, 6Osaka Kaisei Hospital, Osaka, Japan, 7Kansai Rosai Hospital, Hyogo, Japan, and 8Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan

Keywords
Dynapenia, Sarcopenia, Type 1 and type 2 diabetes

*Correspondence
Munehide Matsuhisa
Tel.: +81-88-633-7587
Fax: +81-88-633-7589
E-mail address: matuhisa@tokushima-u.ac.jp

J Diabetes Investig 2021; 12: 1050–1059
doi: 10.1111/jdi.13436

INTRODUCTION
Aging-related muscle loss and weakness, known as sarcopenia1,2, is currently recognized as a diabetic complication3,4, and might contribute to incidental falls and frailty in patients with diabetes5. Sarcopenia was diagnosed as an aging-related muscle weakness accompanied with loss of muscle mass and physical performance by a recent revised consensus of the Asian Working Group for Sarcopenia (AWGS)2. In a previous study, the
prevalence of sarcopenia according to the AWGS 2014 criteria was reported to be 4-11% in general older adults, whereas a higher prevalence (14.8%) has been reported in patients with type 2 diabetes. In addition, sarcopenia can increase the risk of mortality in type 2 diabetes mellitus. However, the prevalence and clinical characteristics of sarcopenia have not been determined in patients with type 1 diabetes mellitus.

Manini et al. proposed that an aging-related impairment of muscle strength without reducing muscle mass should be determined as dynapenia. As dynapenia is not associated with low muscle volume, it might be caused by different pathogenic factors from sarcopenia. Therefore, muscular weakness should be classified as sarcopenia and dynapenia separately according to the presence and absence of low skeletal muscle mass. A previous study showed that the decline in knee extension strength in the group with the highest quartile of glycated hemoglobin (HbA1c) seemed to start when the patients were aged in their 40s. In addition, a longer duration of diabetes (≥6 years) and poor glycemic control (HbA1c >8.0%) were associated with even lower knee extension strength. However, the detail of clinical characteristics of dynapenia with regard to the quality of life (QOL) and incidental falls in patients with type 1 diabetes and type 2 diabetes have not yet been evaluated.

Therefore, the present study intended to clarify the prevalence and clinical characteristics, especially the QOL and incidental falls, of sarcopenia and dynapenia in Japanese patients with type 1 diabetes and type 2 diabetes.

**METHODS**

**Study design and participants**

The present cross-sectional study was approved by the ethics committee of Tokushima University Hospital (approval #2281-9). This was a multi-institutional joint cross-sectional study of seven medical centers on the Impact of Diabetes Mellitus on Dynapenia (iDIAMOND) Study. We recruited individuals without diabetes from the community in the Harima region, Hyogo prefecture, and people who underwent health checkups in the Tokushima University Hospital (Tokushima, Japan) and Osaka Rosai Hospital (Osaka, Japan). The inclusion criteria were patients with type 1 diabetes and type 2 diabetes who were aged ≥30 years. Patients using steroids and those with stroke-induced quadriplegia, myopathy or mobility disability were excluded. In addition, individuals without diabetes aged ≥30 years were included as the control group. All participants gave written informed consent. In the present study, type 1 diabetes and type 2 diabetes was defined by a physician’s diagnosis and medical chart review. Elderly adults were defined as those aged ≥65 years.

**Assessments of bodyweight and composition**

Bodyweight and skeletal muscle mass were measured using a multifrequency bioelectrical impedance analysis (In Body bioelectrical impedance analyzer; In Body Japan, Tokyo, Japan). Obesity was defined as a body mass index (BMI) of ≥25.0 kg/m², while underweight was defined as a BMI of <18.5 kg/m² according to the criteria of obesity reported by the Japan Society for the Study of Obesity. The skeletal muscle mass index (SMI) was calculated by dividing the total skeletal muscle mass of upper and lower limbs by the squared height.

**Assessments of muscle strength and physical performance**

The strengths of grip and knee extension were evaluated as indicators of muscle strength, and gait speed also was determined to evaluate physical performance. The maximum isometric grip strength in each hand was measured in a standing position (GRIP-D TTK5401; Takei, Niigata, Japan). The maximum isometric lower-extremity knee extension strength torque was determined using a hand-held dynamometer (μTas F-1; ANIMA, Tokyo, Japan). The participants sat on a bench and the force sensor was fixed firmly by a belt to the distal end of the tibia to a rigid bar. We multiplied the maximal isometric knee extension strength and the lever arm strength to calculate knee extension torque (Nm). The knee extension strength was evaluated by the knee extension strength torque divided by the bodyweight (Nm/kg). For the usual gait speed, participants were instructed to walk a distance of 10 m at a speed that was normal to them, and the length of time that it took to walk 4 m (3–7 m) was measured.

**Definitions of sarcopenia and dynapenia**

Sarcopenia was diagnosed according to the definition of the AWGS 2019 criteria, which involves a low grip strength, slow gait speed, and low SMI (cut-off values shown in Table S1). Dynapenia was defined according to the previous proposal by Manini and Clark as a low grip and knee extension strength with normal SMI. Participants who were not diagnosed with sarcopenia or dynapenia were categorized as robust.

**Clinical data**

The duration of diabetes, HbA1c value, ratio of urinary albumin to creatinine, estimated glomerular filtration rate (eGFR), diabetic neuropathy, diabetic retinopathy (including simple diabetic retinopathy, pre-proliferative diabetic retinopathy and proliferative diabetic retinopathy), and medicines for diabetes, hypertension and dyslipidemia were collected from the medical records or an interview survey. The eGFR was calculated using the following equation obtained from the Japanese Society of Nephrology: eGFR (male) = 194 × Cr−1.094 × age−0.287; eGFR (female) = 194 × Cr−1.094 × age−0.287 × 0.73914. We defined diabetic neuropathy according to the simplified diagnostic criteria of diabetic polyneuropathy proposed by the consensus of the Japanese study group of diabetic neuropathy. In this criteria, diabetic neuropathy was diagnosed when the patients matched two items out of three items, such as bilateral symptoms of extremities, decreased Achilles tendon reflex and shortened vibration sensory of lower extremities.
Assessments of the health-related QOL and physical activity
The health-related QOL of the surveyed participants was estimated using the Short-Form 8 Health Survey. The questionnaire consists of questions measuring the physical component summary and the mental component summary in relation to health concepts.

Physical activity was evaluated by a diagnostic survey with a short version of the International Physical Activity Questionnaire for each participant. The weekly energy consumption (EC) expressed as kilocalories per week was calculated from the data collected from the questionnaires.

History of incidental falls
The history of incidental falls was obtained from a medical interview using the care prevention checklist, the reliability and validity of which have been evaluated in Japanese individuals. Incidental fall was defined as one or more falls in the past year.

Statistical analysis
The SPSS Statistics 22 software program (IBM Japan, Tokyo, Japan) was used to carry out the statistical analyses. All data are presented as the mean ± standard deviation. Intergroup comparisons (individuals without diabetes vs type 1 diabetes patients vs type 2 diabetes patients or robust vs sarcopenia vs dynapenia) were assessed using an unpaired one-way analysis of variance or an unpaired t-test (continuous variables), χ²-test (categorical variables), analysis of covariance (adjusted analysis, continuous variables) and Mantel-Haenszel test (adjusted analysis, categorical variables). Multivariate logistic regression analyses were used to calculate the cross-sectional association of sarcopenia and dynapenia in type 1 diabetes or type 2 diabetes patients (input of covariates in type 1 diabetes and type 2 diabetes: age ≥65 years, female, BMI ≥25.0 kg/m² or BMI <18.5 kg/m², HbA1c ≥8.0%, diabetic neuropathy, eGFR <30 mL/min/1.73 m², EC of ≥3 Mets). The odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using logistic regression models. Covariates in the multivariate logistic regression analyses were selected using a forced entry method. P-values of <0.05 were considered to show statistical significance.

RESULTS
Prevalence rate of sarcopenia and dynapenia
A total of 1,328 Japanese participants (individuals without diabetes, n = 506; type 1 diabetes patients, n = 177; type 2 diabetes patients, n = 645) were enrolled in the present study (Tables S2–S5). The prevalence rate of sarcopenia and dynapenia in individuals without diabetes and in type 1 diabetes and type 2 diabetes patients is shown in Figure 1.

Among elderly participants aged ≥65 years, type 1 diabetes was associated with the highest prevalence rate of sarcopenia (Figure 1; vs non-diabetes, P < 0.001; vs type 2 diabetes mellitus, P = 0.003). Sarcopenia was also more frequently observed in elderly patients with type 2 diabetes than in individuals without diabetes (P < 0.001). In contrast, in these elderly participants, type 1 diabetes mellitus and type 2 diabetes mellitus were associated with an equally higher prevalence rate of dynapenia than in individuals without diabetes (Figure 1; type 1 diabetes patients vs individuals without diabetes, P < 0.001; type 2 diabetes patients vs individuals without diabetes, P < 0.001). In patients aged 50–64 years, type 2 diabetes patients also showed a significantly higher prevalence rate of dynapenia than in individuals without diabetes (type 2 diabetes patients vs individuals without diabetes, P = 0.030).

Among elderly participants aged ≥65 years, patients with type 1 diabetes showed a significantly higher rate of low SMI, grip strength and knee extension strength than type 2 diabetes patients and individuals without diabetes (low SMI: vs individuals without diabetes, P < 0.001; vs type 2 diabetes patients, P = 0.043; low grip strength: vs individuals without diabetes, P < 0.001; vs type 2 diabetes patients, P = 0.026; low knee extension strength: vs individuals without diabetes, P < 0.001; vs type 2 diabetes patients, P = 0.008). In elderly patients with type 2 diabetes, the prevalence rates of low SMI, grip strength and knee extension strength were significantly higher than those of individuals without diabetes (low SMI: P < 0.001, low grip strength: P < 0.001, low knee extension strength: P < 0.001). Patients who were aged 50–64 years with type 1 diabetes and type 2 diabetes showed a significantly higher rate of low grip strength and low knee extension strength than individuals without diabetes (low grip strength: type 1 diabetes patients, P = 0.002; type 2 diabetes patients, P = 0.003; low knee extension strength: type 1 diabetes patients and type 2 diabetes patients, P < 0.001).

Clinical characteristics of sarcopenia and dynapenia
The clinical characteristics of sarcopenia and dynapenia in individuals without diabetes, and patients with type 1 diabetes and type 2 diabetes are shown in Tables S3, 1 and 2, respectively.

Sarcopenic patients with type 1 diabetes and type 2 diabetes were significantly older (type 1 diabetes patients and type 2 diabetes patients, P < 0.001) and had significantly higher rates of BMI <18.5 kg/m² (type 1 diabetes and type 2 diabetes, P < 0.001) and diabetic neuropathy (type 1 diabetes, P = 0.031; type 2 diabetes, P = 0.043), and lower EC of ≥3 METs (type 1 diabetes patients, P < 0.047; type 2 diabetes patients, P < 0.001) than robust patients with type 1 diabetes and type 2 diabetes.

Dynapenic patients with type 1 diabetes and type 2 diabetes were older (type 1 diabetes patients, P = 0.005; type 2 diabetes patients, P < 0.001), and showed a higher rate of diabetic neuropathy (type 1 diabetes patients, P = 0.001; type 2 diabetes patients, P < 0.001) and eGFR <30 mL/min/1.73 m² (type 1 diabetes patients and type 2 diabetes patients, P < 0.001) than robust patients with type 1 diabetes and type 2 diabetes. In
addition, dynapenic patients showed a higher rate of BMI ≥25.0 than robust and sarcopenic patients with type 2 diabetes.

Health-related QOL of sarcopenia and dynapenia
Sarcopenic patients with type 1 diabetes and type 2 diabetes have a significantly lower physical QOL than robust patients with type 1 diabetes and type 2 diabetes (type 1 diabetes patients, \( P < 0.001 \); type 2 diabetes patients, \( P = 0.018 \); Tables 1 and 2). Dynapenic patients with type 1 diabetes and type 2 diabetes had a lower physical QOL (type 1 diabetes and type 2 diabetes, \( P < 0.001 \)) than robust patients with type 1 diabetes and type 2 diabetes (Tables 1,2).

The analysis of covariance adjusted by age ≥65 years showed that sarcopenia and dynapenia were associated with a lower physical QOL than a robust status (type 1 diabetes, with sarcopenia: \( P = 0.015 \), with dynapenia: \( P = 0.001 \); type 2 diabetes, with sarcopenia: \( P = 0.036 \), with dynapenia: \( P < 0.001 \); Figure 2). In contrast, neither sarcopenia nor dynapenia affected the mental QOL in patients with type 1 diabetes and type 2 diabetes compared with robust patients.
Incidental falls of sarcopenia and dynapenia

Sarcopenic patients with type 1 diabetes and type 2 diabetes showed a higher rate of incidental falls (type 1 diabetes, $P < 0.001$; type 2 diabetes, $P < 0.001$) than robust patients (Tables 1,2). Dynapenic patients with type 1 diabetes and type 2 diabetes also showed a higher rate of incidental falls (type 1 diabetes patients, $P = 0.004$; type 2 diabetes patients, $P < 0.001$) than robust patients (Tables 1,2).

The analysis using the Mantel–Haenszel test adjusted by age ≥65 years showed that dynapenic patients with type 1 diabetes were associated with a higher rate of incidental falls than a robust status (dynapenia with adjusted age ≥65 years, $P = 0.026$; Figure 2). In patients with type 2 diabetes, sarcopenia and dynapenia were associated with a higher rate of incidental fall than a robust status (with sarcopenia: $P < 0.001$, with dynapenia: $P < 0.001$).

**ORs for the risk of sarcopenia and dynapenia**

The ORs, determined by a multivariate logistic regression analysis, of clinical parameters related to sarcopenia and dynapenia in patients with type 1 diabetes and type 2 diabetes are shown in Table 3.

In patients with type 1 diabetes and type 2 diabetes, age ≥65 years and BMI $<18.5$ kg/m$^2$ were significantly associated with the prevalence of sarcopenia. In addition, HbA1c $\geq 8.0\%$ and EC of $\geq 3$ Mets (kcal/day) was significantly associated with the prevalence of sarcopenia in patients with type 2 diabetes.

In patients with type 1 diabetes, diabetic neuropathy was significantly associated with the prevalence of dynapenia. In patients with type 2 diabetes, female, participants aged ≥65 years, BMI $\geq 25.0$ kg/m$^2$, diabetic neuropathy, eGFR $<30$ mL/min/1.73 m$^2$ and EC of $\geq 3$ Mets (kcal/day) were significantly associated with the prevalence of dynapenia.

**DISCUSSION**

In the present multicenter cross-sectional iDIAMOND study, the prevalence and clinical characteristics, involving the QOL and incidental falls, of sarcopenia and dynapenia were investigated in Japanese individuals without diabetes and patients with type 1 diabetes and type 2 diabetes. We used the new AWGS 2019 criteria to describe the prevalence of diabetes-related sarcopenia in patients with type 1 diabetes and type 2 diabetes compared with individuals without diabetes. The present findings provide basic epidemiological data comparing the prevalence of sarcopenia in type 1 diabetes patients and type 2 diabetes patients in an Asian population.

We showed for the first time that the prevalence of sarcopenia in patients with type 1 diabetes was significantly higher than that in patients with type 2 diabetes and individuals without diabetes among elderly adults, according to the newly established criteria of sarcopenia for an Asian population (Figure 1). Sarcopenia is reported to be associated with aging, an underweight status (e.g., malnutrition and low protein intake) and chronic disease, including diabetes. Indeed, older age and underweight status were associated with sarcopenia in all
Dynapenia and sarcopenia diabetes

Table 2 | Clinical characteristics of the study patients with type 2 diabetes mellitus according to the presence of sarcopenia and dynapenia

| Age (years) | 60.4 ± 11.5 | 72.4 ± 7.9 | <0.001 | 698 ± 9.1 | <0.001 | 30.59 |
| Female (%) | 37.3 | 38.2 | 0.879 | 61.0 | 0.001 | 0.015 |
| BMI (kg/m²) | 26.6 ± 5.0 | 21.3 ± 3.4 | <0.001 | 277 ± 4.6 | 0.202 | <0.001 |
| BMI ≥25.0 kg/m² (%) | 59.0 | 105 | <0.001 | 729 | 0.037 | <0.001 |
| BMI <18.5 kg/m² (%) | 24 | 15.8 | <0.001 | 0 | 0.239 | 0.001 |
| Duration of diabetes (years) | 10.7 ± 8.8 | 16.6 ± 11.5 | <0.001 | 15.1 ± 10.3 | 0.002 | 0.642 |
| HbA1c (%) | 89 ± 23 | 92 ± 2.4 | 0.563 | 83 ± 2.0 | 0.091 | 0.046 |
| HbA1c ≥8.0% (%) | 56.6 | 66.7 | 0.125 | 44.8 | 0.070 | 0.012 |
| Urinary albumin/creatinine ratio (mg/gCr) | 165.9 ± 768.2 | 109.2 ± 238.0 | 0.873 | 418.6 ± 1172.7 | 0.102 | 0.127 |
| eGFR (mL/min/1.73 m²) | 75.0 ± 23.8 | 73.3 ± 24.8 | 0.825 | 58.7 ± 24.5 | <0.001 | 0.001 |
| Diabetic neuropathy (%) | 45.5 | 58.1 | 0.043 | 69.5 | <0.001 | 0.166 |
| Diabetic retinopathy, PPDR and PDR (%) | 14.9 | 22.4 | 0.087 | 35.6 | <0.001 | 0.090 |
| eGFR <30 mL/min/1.73 m² (%) | 2.0 | 4.0 | 0.273 | 15.3 | <0.001 | 0.022 |
| Sitting (h/day) | 6.7 ± 43 | 7.7 ± 4.4 | 0.139 | 8.7 ± 5.4 | 0.004 | 0.448 |
| EC of ≥3 Mts (kcal/day) | 189 ± 214 | 88 ± 106 | <0.001 | 85 ± 138 | 0.001 | 0.997 |
| Physical QOL (score) | 45.0 ± 9.1 | 41.7 ± 10.7 | 0.018 | 33.2 ± 11.4 | <0.001 | <0.001 |
| Mental QOL (score) | 47.6 ± 8.8 | 47.0 ± 8.1 | 0.854 | 48.3 ± 9.0 | 0.860 | 0.707 |
| Incidental fall ≥1 times (%) | 7.7 | 30.3 | <0.001 | 492 | <0.001 | 0.025 |

BMI, body mass index; EC, energy consumption; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; PDR, proliferative diabetic retinopathy; PPDR, pre-proliferative diabetic retinopathy; QOL, quality of life. Data are shown as the mean value ± standard deviation.

groups in the present study (Table 2). Chronic hyperglycemia (HbA1c >8.0%), but not diabetic microangiopathy, was also associated with the prevalence of sarcopenia in patients with type 2 diabetes (Table 3), which was comparable to the finding of a previous study. However, the HbA1c level was not associated with the highest prevalence of sarcopenia in patients with type 1 diabetes (Table 3). As the pathophysiology of type 1 diabetes, such as depleted endogenous insulin secretion, increased glucose fluctuation and increased incidence of hypoglycemia, is markedly different from that of type 2 diabetes, other risk factors might contribute to the development of sarcopenia in these patients. O'Neil et al. recently reported that FoxO transcription factors mediate the majority of transcriptional changes in response to increasing protein degradation and muscle atrophy in a streptozotocin-induced rodent model of type 1 diabetes. Therefore, markedly decreased endogenous insulin signaling might impair skeletal muscle mass and strength in patients with type 1 diabetes.

Type 2 diabetes-related sarcopenia has been the focus of previous diabetes treatment practices. Future clinical practices should consider treatment focusing on sarcopenia in type 1 diabetes patients as well as type 2 diabetes patients. Furthermore, our new results are expected to help healthcare professionals who treat elderly patients with type 1 diabetes and type 2 diabetes to diagnose sarcopenia at early stage, and to prevent developing frailty and physical disturbance. We also stimulate the activity of research in the field of diabetes-associated sarcopenia to prevent and slow adverse health outcomes that incur a heavy burden for patients and healthcare systems.

The prevalence of sarcopenia in the present study – 12.2% in individuals without diabetes and 20.9% in type 2 diabetes – appears to be higher than those reported in previous studies, 4–11% in older adults and 14.8% in type 2 diabetes patients. As we defined sarcopenia according to the new definition of AWGS 2019 in which the threshold of grip strength and gait speed were set at lower levels compared with the previous definition of AWGS 2014, the prevalence of sarcopenia might be estimated to be higher in these new criteria than the previous criteria. Indeed, the prevalence rate of sarcopenia determined by the criteria of AWGS 2014 was 10.3% in individuals without diabetes and 16.9% in type 2 diabetes patients, those data were equal to previous studies.

We also found for the first time that the prevalence of dynapenia in elderly patients with type 1 diabetes and type 2 diabetes was equally higher than that in individuals without diabetes, as shown in Figure 1. Furthermore, the prevalence of dynapenia in patients with type 2 diabetes was significantly higher than that in individuals without diabetes, even those who were aged <65 years. In patients with type 1 diabetes and type 2 diabetes, the skeletal muscle mass, which was low, decreased with age, and the low grip and knee extension strength showed a progressive decline before the age of 65 years (Figure 1). As dynapenia was associated with microangiopathy, but not with high glycated hemoglobin (Table 3), muscle weakness might have occurred due to a defect in the micro-environmental condition involving innervation and circulation, but not hyperglycemia itself, in these patients. Indeed, the severity of diabetic neuropathy has been shown to be...
related to muscular weakness in a previous study\textsuperscript{11}. In addition, prolonged chronic hyperglycemia accumulates advanced glycation end-products in several tissues, which induces diabetic angiopathy through chronic inflammation and oxidative stress\textsuperscript{21}. We previously showed that accumulated advanced glycation end-products, determined by skin autofluorescence, was negatively associated with low knee extension strength in patients with type 1 diabetes and type 2 diabetes\textsuperscript{22,23}. In recent studies, obesity was considered to be the cause of sarcopenia\textsuperscript{6}. An obesity status was significantly and independently associated with the risk of dynapenia in patients with type 2 diabetes in the present study (Table 3). In this study, however, sarcopenic obesity was observed in just 2.5\% of elderly patients with type 2 diabetes (date not shown). In contrast, dynapenic obesity was more common (6.7\%) than sarcopenic obesity in patients with type 2 diabetes, so future research on dynapenic obesity will be of interest. Elderly obese patients with type 2 diabetes might thus be at a higher risk of dynapenia, but not sarcopenic obesity. A heavy bodyweight can cause sustained overload on the muscle and increase or maintain its volume. However, we did not evaluate the intramuscular fat, body fat mass by site or adipokine levels; thus, the detailed mechanism underlying the development of dynapenia could not be clarified in the present study.

Finally, this study showed that diabetes patients with sarcopenia and dynapenia have a lower physical QOL and higher rate of incidental falls than robust patients. Sarcopenia has been reported to be associated with a low physical QOL in the general elderly population\textsuperscript{24}. In the present study, sarcopenic patients also showed a lower physical QOL than robust patients with type 1 diabetes and type 2 diabetes mellitus (Figure 2). Thus, sarcopenia impairs the physical QOL, regardless of concomitant diabetes. In addition, a low muscle strength was identified as a discriminator of risk for mobility disability, whereas muscle mass measures were not good discriminators of mortality, incidental falls, mobility disability or instrumental activities of daily living disability\textsuperscript{25}. Thus, muscle weakness might be a major cause of a poor physical QOL and high risk of incidental falls. In addition, as a result of an analysis of covariance adjusted by older age in the present study,
dynapenia showed a lower physical QOL than robust patients with type 1 diabetes and type 2 diabetes. Furthermore, as a result of the Mantel–Haenszel test adjusted by elderly in the present study, dynapenia represented a higher rate of incidental falls than robust in patients with type 1 diabetes] and type 2 diabetes (Figure 2). As both type 1 diabetes and type 2 diabetes patients are associated with an impaired bone structure quality, which is related to an increased fracture rate and delayed fracture healing, it is necessary to consider methods of preventing incidental falls in patients with type 1 diabetes and type 2 diabetes. In contrast, patients with type 1 diabetes and type 2 diabetes who had a history of incidental falls showed a higher rate of diabetic neuropathy and advanced retinopathy than patients with non-incidental falls (date were not shown). Therefore, dynapenia itself, as well as associated clinical features, such as aging and diabetic microangiopathy, might contribute to incidental falls. To clarify the influence of sarcopenia and dynapenia on physical QOL and incidental falls in patients with diabetes, further prospective studies will be necessary.

Several limitations associated with the present study warrant mention. First, it was impossible to infer causality because of the cross-sectional design. Second, we estimated the muscle mass using BIA-based measurements, not dual-energy X-ray absorptiometry. However, BIA measurements have been reported to be strongly correlated with dual-energy X-ray absorptiometry among older individuals, and the recent criteria of sarcopenia in the European Working Group on Sarcopenia in Older People and AWGS allow us to use the BIA method as well as the dual-energy X-ray absorptiometry method clinically. Third, clinical characteristics, such as age, sex and BMI, were inconsistent among individuals without diabetes, type 1 diabetes patients and type 2 diabetes patients. Fourth, how reliably we captured the history of fall events in the present study was unclear. In addition, the clinical relevance of falls that occurred in the past to the current presence of sarcopenia or dynapenia was unclear – usually the temporality is reversed. Finally, the number of patients with type 1 diabetes who had dynapenia was relatively small.

In conclusion, sarcopenia and dynapenia were frequently observed in patients with type 1 diabetes and type 2 diabetes compared with individuals without diabetes, and were associated with poor physical QOL and high incidental falls, especially dynapenia.

### Table 3 | Odds ratios of sarcopenia and dynapenia complications in type 1 diabetes and type 2 diabetes patients

|                       | Type 1 diabetes patients | Type 2 diabetes patients |
|-----------------------|--------------------------|--------------------------|
|                       | Multivariate             | Multivariate             |
|                       | ORs  | 95% CIs       | P-value | ORs  | 95% CIs       | P-value |
| Age ≥65 years         |      |               |         |      |               |         |
| Female                | 5.283 | 1.713–16.290  | 0.004   | 13.067 | 5.432–31.432  | <0.001   |
| BMI <18.5 kg/m²        | 0.646 | 0.209–1.997   | 0.448   | 0.609 | 0.338–1.098   | 0.099    |
| HbA1c ≥8.0%           | 21.062 | 3.573–124.139 | 0.001   | 6.007 | 2.144–16.833  | 0.001    |
| Diabetic neuropathy   | 0.784 | 0.251–2.455   | 0.676   | 2.044 | 1.141–3.662   | 0.016    |
| eGFR <30 mL/min/1.73 m² | 1.695 | 0.571–5.033   | 0.342   | 0.972 | 0.549–1.721   | 0.222    |
| EC of ≥3 Mets (kcal/day) | 0.628 | 0.060–6.553   | 0.698   | 0.801 | 0.209–3.067   | 0.746    |
|                       | 0.997 | 0.993–1.001   | 0.136   | 0.995 | 0.993–0.998   | <0.001   |

|                       | Type 1 diabetes patients | Type 2 diabetes patients |
|-----------------------|--------------------------|--------------------------|
|                       | Multivariate             | Multivariate             |
|                       | ORs  | 95% CIs       | P-value | ORs  | 95% CIs       | P-value |
| Age ≥65 years         |      |               |         |      |               |         |
| Female                | 1.494 | 0.204–10.941  | 0.693   | 4.699 | 2.310–9.558   | <0.001   |
| BMI ≥25.0 kg/m²       | 8.193 | 0.309–217.489 | 0.209   | 3.015 | 1.603–5.672   | 0.001    |
| HbA1c ≥8.0%           | 0.870 | 0.042–18.047  | 0.929   | 3.645 | 1.847–7.195   | <0.001   |
| Diabetic neuropathy   | 0.481 | 0.055–4.214   | 0.508   | 0.666 | 0.359–1.235   | 0.197    |
| eGFR <30 mL/min/1.73 m² | 18.050 | 1.359–239.777 | 0.028   | 2.529 | 1.310–4.880   | 0.006    |
| EC of ≥3 Mets (kcal/day) | 33.912 | 0.760–152.575 | 0.069   | 4.130 | 1.448–11.782  | 0.008    |
|                       | 0.997 | 0.987–1.008   | 0.606   | 0.997 | 0.994–0.999   | 0.015    |

BMI, body mass index; CIs, confidence intervals; EC, energy consumption; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; ORs, odds ratios.
ACKNOWLEDGMENTS

This work was supported by the Japan Agency for Medical Research and Development (16lk101002h0002). We thank Professor Yasunobu Tokuda for his excellent support of this study.

DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

1. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16–31.
2. Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc 2020; 21: 300–307.
3. Park SW, Goodpaster BH, Lee JS, et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 2009; 32: 1993–1997.
4. Park SW, Goodpaster BH, Strotmeyer ES, et al. Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study. Diabetes 2006; 55: 1813–1818.
5. Tanimoto Y, Watanabe M, Sun W, et al. Sarcopenia and falls in community-dwelling elderly subjects in Japan: defining sarcopenia according to criteria of the European Working Group on Sarcopenia in Older People. Arch Gerontol Geriatr 2014; 59: 295–299.
6. Chen LK, Lee WJ, Peng LN, et al. Recent advances in sarcopenia research in Asia: 2016 update from the Asian Working Group for Sarcopenia. J Am Med Dir Assoc 2016; 17: 767.e1–7.
7. Wang T, Feng X, Zhou J, et al. Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly. Sci Rep 2016; 6: 38937.
8. Beretta MV, Dantas Filho FF, Freiberg RE, et al. Sarcopenia and type 2 diabetes mellitus as predictors of 2-year mortality after hospital discharge in a cohort of hospitalized older adults. Diabetes Res Clin Pract 2020; 159: 107969.
9. Manini TM, Clark BC. Dynapenia and aging: an update. J Gerontol A Biol Sci Med Sci 2012; 67: 28–40.
10. Kalyani RR, Metter EJ, Egan J, et al. Hyperglycemia predicts persistently lower muscle strength with aging. Diabetes Care 2015; 38: 82–90.
11. Nomura T, Ishiguro T, Ohira M, et al. Diabetic polyneuropathy is a risk factor for decline of lower extremity strength in patients with type 2 diabetes. J Diabetes Invest 2018; 9: 186–192.
12. Hayakawa M, Sakurai Y, Kato E. Estimation of basal energy expenditure predicted by the tibial length in Japanese elderly patients. Jpn J Surg Metab Nutr 2003; 37: 297–304 (Japanese).
13. Manini TM, Visser M, Won-Park S, et al. Knee extension strength cutpoints for maintaining mobility. J Am Geriatr Soc 2007; 55: 451–457.
14. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982–992.
15. Syddall HE, Martin HJ, Harwood RH, et al. The SF-36: a simple, effective measure of mobility-disability for epidemiological studies. J Nutr Health Aging 2009; 13: 57–62.
16. Craig CL, Marshall AL, Sjöström M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003; 35: 1381–1395.
17. IPAQ Research Committee. International physical activity questionnaire. Available from: https://sites.google.com/site/ theipaq/scoring-protocol Accessed July 30, 2016.
18. Murayama H, Nishi M, Shimizu Y, et al. The Hatoyama Cohort Study: design and profile of participants at baseline. J Epidemiol 2012; 22: 551–558.
19. Sugimoto K, Tabara Y, Ikegami H, et al. Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: the multicenter study for clarifying evidence for sarcopenia in patients with diabetes mellitus. J Diabetes Invest 2019; 10: 1471–1479.
20. O’Neill BT, Bhardwaj G, Penniman CM, et al. FoxO transcription factor are critical regulators of diabetes-related muscle atrophy. Diabetes 2019; 68: 556–570.
21. Singh R, Barden A, Mori T, et al. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129–146.
22. Mori H, Kuroda A, Araki M, et al. Advanced glycation end-products are a risk for muscle weakness in Japanese patients with type 1 diabetes. J Diabetes Invest 2017; 8: 377–382.
23. Mori H, Kuroda A, Ishizu M, et al. Association of accumulated advanced glycation end products with a high prevalence of sarcopenia and dynapenia in patients with type 2 diabetes. J Diabetes Invest 2019; 10: 1332–1340.
24. Tsekoura M, Kastrinis A, Katsoulaki M, et al. Sarcopenia and its impact on quality of life. Adv Exp Med Biol 2017; 987: 213–218.
25. Cawthon PM, Travison TG, Manini TM, et al. Establishing the link between lean mass and grip strength cut-points with mobility disability and other health outcomes: proceedings of the sarcopenia definition and outcomes consortium conference. J Gerontol A Biol Sci Med Sci 2020; 75: 1317–1323.
26. Patel S, Hyer S, Tweed K, et al. Risk factors for fractures and falls in older women with type 2 diabetes mellitus. Calcif Tissue Int 2008; 82: 87–91.
27. Asadipooya K, Uy EM. Advanced glycation end products (AGEs), receptor for AGEs, diabetes, and bone: review of the literature. J Endocr Soc 2019; 3: 1799–1818.
28. Abdulameer SA, Syed Sulaiman SA, Hassali MA, et al. Is there a link between osteoporosis and type 1 diabetes?
SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1 | Cut-off values of a low skeletal muscle mass index, low grip strength, and slow gait speed according to the definitions of sarcopenia and dynapenia.

Table S2 | Clinical characteristics of all participants (S2–1), and participants aged 30–49 years (S2–2), 50–64 years old (S2–3) and ≥65 years (S2–4) among individuals without diabetes, type 1 diabetes patients and type 2 diabetes patients.

Table S3 | Medications of the study patients with type 1 diabetes according to the presence of sarcopenia and dynapenia.

Table S4 | Medications of the study patients with type 2 diabetes according to the presence of sarcopenia and dynapenia.

Table S5 | Numbers of enrolled participants without diabetes, and with type 1 diabetes and type 2 diabetes in each medical center and community center.